Keywords: مهار کننده فاکتور Xa; AF; atrial fibrillation; AMI; acute myocardial infarction; ASMD; absolute standardized mean difference; GIB; gastrointestinal bleeding; ICD-9-CM; International Classification of Diseases-Ninth Revision-Clinical Modification; ICD-10-CM; International Class
مقالات ISI مهار کننده فاکتور Xa (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: مهار کننده فاکتور Xa; Cerebrovascular complication; DOAC; direct thrombin inhibitor; factor Xa inhibitor; efficacy and safety; PMDA;
Keywords: مهار کننده فاکتور Xa; direct thrombin inhibitor; factor Xa inhibitor; hemorrhage; mortality; warfarin; AF; atrial fibrillation; AMI; acute myocardial infarction; ASMD; absolute standardized mean difference; CI; confidence interval; CKD; chronic kidney disease; GI; gastrointest
Improvement of distal acquired demyelinating symmetric (DADS) neuropathy after exposure to factor Xa inhibitor
Keywords: مهار کننده فاکتور Xa; DADS neuropathy; Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP); Factor Xa inhibitor; Rivaroxaban; Demyelinating neuropathy;
Edoxaban improves acute venous thromboembolism while preserving protein C and protein S levels
Keywords: مهار کننده فاکتور Xa; Acute venous thromboembolism; Anticoagulants; Factor Xa inhibitor;
The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan
Keywords: مهار کننده فاکتور Xa; AF; atrial fibrillation; AKI; acute kidney injury; CHA2DS2-VASc; congestive heart failure, hypertension, aged 75â¯years or older, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, aged 65 to 74â¯years, female; CKD; chronic
Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome
Keywords: مهار کننده فاکتور Xa; acute coronary syndrome; factor Xa inhibitor; net clinical outcome; risk-benefit; rivaroxaban; ACS; acute coronary syndrome; CV; cardiovascular; ICH; intracranial hemorrhage; MI; myocardial infarction; TIMI; Thrombolysis In Myocardial Infarction;
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke
Keywords: مهار کننده فاکتور Xa; Stroke volume; recurrent; NOAC; DOAC; direct thrombin inhibitor; dabigatran; factor Xa inhibitor; rivaroxaban; apixaban; edoxaban; warfarin;
Pre-clinical pharmacodynamic study of a novel oral factor Xa inhibitor zifaxaban
Keywords: مهار کننده فاکتور Xa; Bleeding; Clotting time; Factor Xa inhibitor; Thrombosis; Zifixaban;
Characterization of a novel selective factor Xa inhibitor, DJT06001, which reduces thrombus formation with low risk of bleeding
Keywords: مهار کننده فاکتور Xa; Anticoagulant; Blood coagulation; Factor Xa inhibitor; Hemostasis; Thrombosis;
Polyphenolic-polysaccharide conjugates from flowers and fruits of single-seeded hawthorn (Crataegus monogyna Jacq.): Chemical profiles and mechanisms of anticoagulant activity
Keywords: مهار کننده فاکتور Xa; Crataegus monogyna; Anticoagulant activity; Factor Xa inhibitor;
Monitoring of anti-Xa activity and factors related to bleeding events: A study in Japanese patients with nonvalvular atrial fibrillation receiving rivaroxaban
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitor; Nonvalvular atrial fibrillation; Coagulation test; Bleeding complication;
An efficient stereoselective synthesis of six stereoisomers of 3, 4-diaminocyclohexane carboxamide as key intermediates for the synthesis of factor Xa inhibitors
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitor; Stereoselective synthesis; 3,4-Diaminocyclohexane carboxamide; Gram scale synthesis;
Clinical research studyMortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial
Keywords: مهار کننده فاکتور Xa; Anticoagulant; Bleeding; Death; Edoxaban; Factor Xa inhibitor; Hemorrhage; Warfarin;
Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis after Hip and Knee Arthroplasty
Keywords: مهار کننده فاکتور Xa; rivaroxaban; enoxaparin; DVT; PE; VTE; factor Xa inhibitor
Ecotin: Exploring a feasible antithrombotic profile
Keywords: مهار کننده فاکتور Xa; Ecotin; Thrombin inhibitor; Factor Xa inhibitor; Ecotin-WT; ecotin wild type; ecotin-RR; ecotin with two mutations at the primary binding site; TF.FVIIa; tissue factor-factor VIIa; PT; prothrombin time; APTT; activated partial thromboplastin time; TT; t
Regular ArticleClinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Factor Xa Inhibitor DY-807f in Healthy Volunteers
Keywords: مهار کننده فاکتور Xa; DY-807f; Factor Xa inhibitor; Venous thromboembolism; Atrial fibrillation;
Structure-guided creation of AcAP5-derived and platelet targeted factor Xa inhibitors
Keywords: مهار کننده فاکتور Xa; Percutaneous coronary intervention; Platelet targeted delivery; Factor Xa inhibitor; AcAP5; RGD
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials
Keywords: مهار کننده فاکتور Xa; Venous thromboembolism; Factor Xa inhibitor; Rivaroxaban; Apixaban; Enoxaparin; Total knee replacement;
Rivaroxaban attenuates leukocyte adhesion in the microvasculature and thrombus formation in an experimental mouse model of type 2 diabetes mellitus
Keywords: مهار کننده فاکتور Xa; rivaroxaban; Factor Xa inhibitor; type 2 diabetes mellitus; leukocyte-endothelial interaction; venous thrombosis;
Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation : Insights From the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation)
Keywords: مهار کننده فاکتور Xa; atrial fibrillation; cardioversion; factor Xa inhibitor; thromboembolic events; vitamin K antagonistAF, atrial fibrillation; MI, myocardial infarction
Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes
Keywords: مهار کننده فاکتور Xa; atrial fibrillation; bleeding; factor Xa inhibitor; AF; atrial fibrillation; CI; confidence interval; HR; hazard ratio; INR; international normalized ratio; ISTH; International Society on Thrombosis and Haemostasis; TIA; transient ischemic attack;
Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats
Keywords: مهار کننده فاکتور Xa; APTT; activated partial thromboplastin time; BID; twice daily; DVT; deep vein thrombosis; factor Xa; activated factor X; HE; hematoxylin and eosin; PE; pulmonary embolism; PT; prothrombin time; PTAH; phosphotungstic acid hematoxylin; QD; once daily; S.E.M
Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, for Thromboprophylaxis After Total Hip Arthroplasty in Japan and Taiwan
Keywords: مهار کننده فاکتور Xa; edoxaban; factor Xa inhibitor; thromboembolic events; total hip arthroplasty; enoxaparin;
Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation : The ENGAGE AF–TIMI 48 Trial
Keywords: مهار کننده فاکتور Xa; anticoagulation; atrial fibrillation; edoxaban; factor Xa inhibitor; new oral anticoagulants; vitamin K antagonistAF, atrial fibrillation; factor Xa, activated factor X; INR, international normalized ratio; NOAC, new oral anticoagulant; SEE, systemic embo
Clinical research studyPatterns of Initiation of Oral Anticoagulants in Patients with Atrial Fibrillation- Quality and Cost Implications
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitor; Novel anticoagulant; Patterns of use; Vitamin K antagonist; Warfarin;
A new peptide (Ruviprase) purified from the venom of Daboia russelii russelii shows potent anticoagulant activity via non-enzymatic inhibition of thrombin and factor Xa
Keywords: مهار کننده فاکتور Xa; Anticoagulant peptide; Biosensor analysis; Daboia russelii russelii; Factor Xa inhibitor; Protein-protein interaction; Thrombin inhibitor; ALP; alkaline phosphatase; AT-III; antithrombin-III; BLASTP; basic local alignment search tool; CD; circular dichr
Pharmacological properties and pathophysiological significance of a Kunitz-type protease inhibitor (Rusvikunin-II) and its protein complex (Rusvikunin complex) purified from Daboia russelii russelii venom
Keywords: مهار کننده فاکتور Xa; Biological role; Factor Xa inhibitor; Serine protease inhibitor; Thrombin inhibitor; Venom protein complex; Toxicity
In stent restenosis and thrombosis assessment after EP224283 injection in a rat model
Keywords: مهار کننده فاکتور Xa; Atherosclerosis; EP224283; In-stent restenosis; GPIIbIIIa antagonist; Factor Xa inhibitor; Stent thrombosis;
Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis
Keywords: مهار کننده فاکتور Xa; Oral anticoagulant; Factor Xa inhibitor; Venous thrombosis; Bleeding; Platelet;
Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51
Keywords: مهار کننده فاکتور Xa; acute coronary syndrome(s); factor Xa inhibitor; rivaroxaban; stent thrombosisACS, acute coronary syndrome(s); DAPT, dual antiplatelet therapy; PCI, percutaneous coronary intervention
Effect of the Factor Xa Inhibitor Rivaroxaban on Arterial Thrombosis in Wild-Type and Apolipoprotein E-Deficient Mice
Keywords: مهار کننده فاکتور Xa; ApoE, apolipoprotein E; BW, body weight; VTE, Venous thrombosis and thromboembolism; WT, wild-typearterial thrombosis; factor Xa inhibitor; photochemical injury; rivaroxaban
Cardiovascular PharmacologyMelagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats
Keywords: مهار کننده فاکتور Xa; Edoxaban; Factor Xa inhibitor; Tissue factor; Hypercoagulation; Thrombin inhibitor;
Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: Phase III randomized, mechanical prophylaxis-controlled, open-label study
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitor; Venous thromboembolism; Abdominal surgery; Japan
The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2011
Keywords: مهار کننده فاکتور Xa; factor Xa inhibitor; rivaroxaban; apixaban; direct thrombin inhibitor; dabigatran; blood conservation guidelines; aminocaproic acid; tranexamic acid; antifibrinolytics; erythropoietin; clopidogrel; platelet blockade; point-of-care testing; fresh frozen pl
Arylsulfonamidopiperidone derivatives as a novel class of factor Xa inhibitors
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitor; Bioisostere; Valerolactam; Arylsulfonamide; Antithrombotic agent; X-ray crystal structure
Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor
Keywords: مهار کننده فاکتور Xa; Oral anticoagulant; Factor Xa inhibitor; Thrombosis; Glucuronidation; Antithrombin; Bleeding
Orally active zwitterionic factor Xa inhibitors with long duration of action
Keywords: مهار کننده فاکتور Xa; Anticoagulant; Factor Xa; Factor Xa inhibitor; Zwitter ionic compound
Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic additives in its oral dosage form
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitor; Bioavailability; Bile acid; Nanosphere; Cholestyramine; Electrostatic interaction;
Design, synthesis and SAR of novel ethylenediamine and phenylenediamine derivatives as factor Xa inhibitors
Keywords: مهار کننده فاکتور Xa; Anticoagulant; Factor Xa inhibitor; Phenylenediamine; Ethylenediamine
Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa
Keywords: مهار کننده فاکتور Xa; Piperidine-4-carboxamide; Factor Xa inhibitor; Anticoagulant; Thromboembolism;
2-Aminomethylphenylamine as a novel scaffold for factor Xa inhibitor
Keywords: مهار کننده فاکتور Xa; LMUFNFLXBDOGET-UHFFFAOYSA-N; fXa; factor Xa; PTCT2; clotting time doubling concentration for prothrombin time; JP1; Japanese Pharmacopoeia First Fluid; JP2; Japanese Pharmacopoeia Second Fluid; Anticoagulant; Factor Xa; Factor Xa inhibitor; New diamine li
Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SAR
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitor; Anticoagulant; Anthranilamide; Benzamidine; N,N-Dialkylbenzamidine
Cyanoguanidine-based lactam derivatives as a novel class of orally bioavailable factor Xa inhibitors
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitor; Cyanoguanidine; Bioisostere; Thiourea; Ketene aminal; Bioavailable;
Aroylguanidine-based factor Xa inhibitors: The discovery of BMS-344577
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitor; Aroylguanidine; CYP3A4 inhibition; Orally active;
Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit
Keywords: مهار کننده فاکتور Xa; Anticoagulant; Oral bioavailability; Factor Xa inhibitor; Biased screen; Computer-aided design; X-ray analysis; Clotting assay
Synthesis and biological evaluation of the metabolites of 2-(1-{3-[(6-chloronaphthalen-2-yl)sulfonyl]propanoyl}piperidin-4-yl)-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitor; Antithrombotic agent; Active metabolite
Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: Exploration of 6–6 fused rings as alternative S1 moieties
Keywords: مهار کننده فاکتور Xa; Anticoagulant; Factor Xa inhibitor; Solubility; Food effect
Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part I: Exploration of 5–6 fused rings as alternative S1 moieties
Keywords: مهار کننده فاکتور Xa; Anticoagulant; Factor Xa inhibitor; Food effect; Solubility
Design, synthesis, and biological activity of piperidine diamine derivatives as factor Xa inhibitor
Keywords: مهار کننده فاکتور Xa; Factor Xa inhibitor; Anticoagulant; cis-Piperidine diamine derivative